NORTHSTAR ASSET MANAGEMENT Co Purchases 15 Shares of Eli Lilly and Company $LLY

NORTHSTAR ASSET MANAGEMENT Co lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 910 shares of the company’s stock after buying an additional 15 shares during the quarter. NORTHSTAR ASSET MANAGEMENT Co’s holdings in Eli Lilly and Company were worth $709,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Carrera Capital Advisors grew its holdings in Eli Lilly and Company by 6.8% in the second quarter. Carrera Capital Advisors now owns 676 shares of the company’s stock worth $527,000 after purchasing an additional 43 shares during the period. PKO Investment Management Joint Stock Co lifted its position in Eli Lilly and Company by 50.3% during the second quarter. PKO Investment Management Joint Stock Co now owns 14,426 shares of the company’s stock valued at $11,245,000 after purchasing an additional 4,826 shares during the period. Sage Mountain Advisors LLC lifted its position in Eli Lilly and Company by 0.5% during the second quarter. Sage Mountain Advisors LLC now owns 5,732 shares of the company’s stock valued at $4,468,000 after purchasing an additional 27 shares during the period. AlphaQuest LLC lifted its position in Eli Lilly and Company by 18.2% during the second quarter. AlphaQuest LLC now owns 325 shares of the company’s stock valued at $253,000 after purchasing an additional 50 shares during the period. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its position in Eli Lilly and Company by 18.2% during the second quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,820 shares of the company’s stock valued at $1,419,000 after purchasing an additional 280 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 in the last ninety days. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Wall Street Zen downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Berenberg Bank reiterated a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. HSBC increased their price target on shares of Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Finally, Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $938.61.

Eli Lilly and Company Stock Up 0.6%

Shares of LLY stock opened at $825.86 on Friday. The company has a market capitalization of $781.65 billion, a price-to-earnings ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47. Eli Lilly and Company has a one year low of $623.78 and a one year high of $935.63. The company’s fifty day moving average price is $768.01 and its 200-day moving average price is $768.14. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue was up 37.6% on a year-over-year basis. During the same period last year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.